Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3001-3008

  Kishimoto, Hiroyuki ^a,b,c   Urata, Yasuo ^e   Tanaka, Noriaki ^c   Fujiwara, Toshiyoshi ^c,d   Hoffman, Robert M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^e National Institute of Infectious Diseases   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; OBP 301; OBP 401; TELOMELYSIN; TELOMELYSIN GREEN FLUORESCENT PROTEIN; TELOMERASE; TELOMESCAN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; GENE; GFP GENE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; MOUSE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; VISCERAL METASTASIS;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HCT116 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70949102751     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0556     Document Type: Article

References (26)

1. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006;25:3848-3856 (Pubitemid 43980480)
2. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225-237
3. Takayasu K, Muramatsu Y, Moriyama N, et al. Clinical and radiologic assessments of the results of hepatectomy for small hepatocellular carcinoma and therapeutic arterial embolization for postoperative recurrence. Cancer 1989;64:1848-1852 (Pubitemid 19267803)
4. Koshariya M, Jagad RB, Kawamoto J, et al. An update and our experience with metastatic liver disease. Hepato-gastroenterology 2007;54:2232-2239
5. Kavolius J, Fong Y, Blumgart LH. Surgical resection of metastatic liver tumors. Surg Oncol Clin N Am 1996;5:337-352 (Pubitemid 26132354)
6. Chouillard E, Cherqui D, Tayar C, Brunetti F, Fagniez PL. Anatomical biand trisegmentectomies as alternatives to extensive liver resections. Ann Surg 2003;238:29-34. (Pubitemid 38176404)
7. Jiao LR, Hansen PD, Havlik R, Mitry RR, Pignatelli M, Habib N. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg 1999;177:303-306 (Pubitemid 29218340)
8. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005;23:8490-8499 (Pubitemid 46260246)
9. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14 Suppl 2:ii13-6.
10. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20, discussion 520-522
11. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-292 (Pubitemid 38114191)
12. Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('telomelysin-RGD'). Oncogene 2005;24:3130-3140 (Pubitemid 40695082)
13. Umeoka T, Kawashima T, Kagawa S, et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004;64:6259-6265 (Pubitemid 39129429)
14. Hashimoto Y, Watanabe Y, Shirakiya Y, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008;99:385-390 (Pubitemid 351228496)
15. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006;12:1213-1219
16. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551-557 (Pubitemid 29076049)
17. Watanabe T, Hioki M, Fujiwara T, et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006;312:256-265
18. Hioki M, Kagawa S, Fujiwara T, et al. Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. Int J Cancer 2008;122:2628-2633 (Pubitemid 351590501)
19. Huang P, Watanabe M, Kaku H, et al. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Ther 2008;15:315-322
20. Fujiwara T, Kagawa S, Kishimoto H, et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 2006;119:432-440 (Pubitemid 43911910)
21. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806.
22. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008;99:1528-1538
23. Yang M, Luiken G, Baranov E, Hoffman RM. Facile whole-body imaging of internal fluorescent tumors in mice with an LED flashlight. Biotechniques 2005;39:170-172
24. Kishimoto H, Zhao M, Hayashi K, et al. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A 2009;106:14514-14517
25. Jasni BR. Green surgery. Science 2009;325:1321.
26. Fujiwara T, Tanaka N, Numunaitis JJ, et al. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer. Evaluation of biodistribution and immune response. J Clin Oncol 2008;26:3572.